Pancreatic Cancer Research

ResearcherNagoya University HospitalActive in the last 2 years

Mitsuhiro Fujishiro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4074-1140; OpenAlex author ID A5056500184, A5112274862, A5122370882, A5135210964. Sources: ClinicalTrials.gov.

Their work

Papers
41 (first author 0, last author 30)
Trials
1
Grants
0
Labs led
2
Collaborators
100
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers, 1 trial · 2022: 13 papers · 2023: 3 papers · 2024: 3 papers · 2025: 9 papers · 2026: 8 papers

Papers 41

  1. Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovori… Last author DOI 10.1007/s00520-026-10845-1↗
  2. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… Co-author DOI 10.1007/s00535-026-02413-5↗
  3. Prediction model for ctDNA detectability in liquid comprehensive genomic profiling of advanced pancreatic cancer based on Japanese real-world data. Co-author DOI 10.1016/j.esmoop.2026.106069↗
  4. Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy. Co-author DOI 10.1016/j.hpb.2025.12.021↗
  5. Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer. Last author DOI 10.1016/j.isci.2026.117071↗
  6. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  7. Hepatocytes promote liver metastasis of pancreatic cancer by providing serine. Co-author DOI 10.1038/s41586-026-11051-z↗
  8. Association between Serum Human Satellite II RNA and miR-21-5p Levels and Time to Pancreatic Cancer Diagnosis in a Prospective Population-based Study. Last author DOI 10.1097/mpa.0000000000002723↗
  9. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Last author DOI 10.1007/s00535-024-02173-0↗
  10. WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway. Last author DOI 10.1007/s00535-024-02192-x↗
  11. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Last author DOI 10.1007/s00535-025-02253-9↗
  12. Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment. Last author DOI 10.1038/s41598-025-32222-4↗
  13. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. Last author DOI 10.1053/j.gastro.2025.04.032↗
  14. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. Last author DOI 10.1097/mpa.0000000000002411↗
  15. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Last author DOI 10.1136/gutjnl-2024-333259↗
  16. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  17. Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstru… Last author DOI 10.5946/ce.2024.031↗
  18. CA19-9-Positive Extracellular Vesicle Is a Risk Factor for Cancer-Associated Thrombosis in Pancreatic Cancer. Last author DOI 10.1016/j.gastha.2024.02.005↗
  19. Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. Last author DOI 10.1016/j.jbc.2024.105742↗
  20. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. Co-author DOI 10.1097/mpa.0000000000002291↗
  21. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  22. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Last author DOI 10.1007/s00520-023-07659-w↗
  23. Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. Last author DOI 10.1111/cas.15910↗
  24. Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. Last author DOI 10.1002/ctm2.1089↗
  25. Comparison of outcomes between secondary fully covered and uncovered self-expandable metal stents in the treatment of recurrent biliary obstruction of pancreat… Last author DOI 10.1007/s00464-021-08981-2↗
  26. Targeting autophagy as a therapeutic strategy against pancreatic cancer. Last author DOI 10.1007/s00535-022-01889-1↗
  27. Smaller extracellular vesicles are released from pancreatic cancer cells by the alteration of the lipid composition under low glucose conditions. Last author DOI 10.1016/j.bbrc.2022.11.040↗
  28. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to … Co-author DOI 10.1038/s41388-022-02288-9↗
  29. Correction: Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreati… Co-author DOI 10.1038/s41388-022-02336-4↗
  30. Author Correction: Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Last author DOI 10.1038/s41598-022-21219-y↗
  31. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Last author DOI 10.1111/cas.15398↗
  32. Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial … Last author DOI 10.1186/s12885-022-09272-2↗
  33. Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer. Last author DOI 10.3389/fcell.2022.1023332↗
  34. The Role of Neural Signaling in the Pancreatic Cancer Microenvironment. Last author DOI 10.3390/cancers14174269↗
  35. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Last author DOI 10.3390/cancers14184351↗
  36. The Role of the Microbiome in Pancreatic Cancer. Last author DOI 10.3390/cancers14184479↗
  37. Utility of multiphase contrast enhancement patterns on CEH-EUS for the differential diagnosis of IPMN-derived and conventional pancreatic cancer. Last author DOI 10.1016/j.pan.2020.12.022↗
  38. Variability measurements provide additional value to shear wave elastography in the diagnosis of pancreatic cancer. Last author DOI 10.1038/s41598-021-86979-5↗
  39. Risks and characteristics of pancreatic cancer and pancreatic relapse in autoimmune pancreatitis patients. Last author DOI 10.1111/jgh.15163↗
  40. Diagnosis of vascular invasion in pancreatic ductal adenocarcinoma using endoscopic ultrasound elastography. Last author DOI 10.1186/s12876-020-01228-9↗
  41. Specific increase in serum autotaxin activity in patients with pancreatic cancer. Co-author DOI 10.1016/j.clinbiochem.2011.03.128↗

Trials 1

  1. Investigator-initiated Clinical Trial of MIKE-1 Study chair NCT05064618↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 18 shared papers, 2011–2026 · strength 3.27
  2. Kazunaga Ishigaki · 13 shared papers, 2022–2026 · strength 2.87
  3. Tatsunori Suzuki · 11 shared papers, 2022–2026 · strength 2.05
  4. Tsuyoshi Hamada · 11 shared papers, 2022–2026 · strength 2.00
  5. Naminatsu Takahara · 8 shared papers, 2023–2026 · strength 1.72
  6. Takahiro Kishikawa · 7 shared papers, 2022–2026 · strength 1.56
  7. Takahiro Seimiya · 7 shared papers, 2022–2026 · strength 1.55
  8. Motoyuki Otsuka · 7 shared papers, 2022–2026 · strength 1.55
  9. Hideaki Ijichi · 6 shared papers, 2022–2026 · strength 1.47
  10. Koji Miyabayashi · 6 shared papers, 2022–2026 · strength 1.39
  11. Kiyoshi Hasegawa · 7 shared papers, 2022–2026 · strength 1.28
  12. Hiroki Oyama · 6 shared papers, 2023–2025 · strength 1.14
  13. Takuya Ishikawa · 9 shared papers, 2020–2022 · strength 1.10
  14. Hiroki Kawashima · 9 shared papers, 2020–2022 · strength 1.10
  15. Eizaburo Ohno · 9 shared papers, 2020–2022 · strength 1.10
  16. Yohei Masugi · 6 shared papers, 2022–2026 · strength 1.07
  17. Chikako Shibata · 5 shared papers, 2022–2026 · strength 1.05
  18. Tadashi Iida · 8 shared papers, 2020–2022 · strength 0.99
  19. Genso Notoya · 4 shared papers, 2024–2026 · strength 0.94
  20. Keisuke Yamamoto · 4 shared papers, 2022–2026 · strength 0.84
  21. Tsuyoshi Takeda · 5 shared papers, 2022–2026 · strength 0.83
  22. Hidenori Kage · 3 shared papers, 2025–2026 · strength 0.68
  23. Yurie Tokito · 3 shared papers, 2025–2026 · strength 0.66
  24. Go Endo · 3 shared papers, 2025–2026 · strength 0.66
  25. Naoki Sasahira · 5 shared papers, 2011–2026 · strength 0.65

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.